BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05462717 (RMC-6291 in Colorectal Cancer patients previously treated with…): BVCT ex-ante prediction vs. reported outcome

On 16 Jul 2023, BioinvestGPT's BVCT predicted no technical call and commercial failure for this trial. The 2 Dec 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05462717
Drug Name
RMC-6291
Drug MoA
tri-complex RAS(ON) multi-selective inhibitor
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
Colorectal Cancer (CRC) patients previously treated with KRAS(OFF) G12C inhibitors
Human Patients
222
Sponsor
Revolution Medicines
Phase
Phase 1

Prediction of , index 1176

Prospective Prediction
Prediction Index
1176
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit non-superior to RAS(OFF) inhibitors)
Technical Prediction
—

Readout of

Prediction Validation
Readout Date
Prediction To Readout
505 days in advance
Readout Data Interpretation
RMC6291 achieved 0% ORR (0% ORR means non-superior to KRAS(OFF) G12C inhibitors)
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Phase
Phase 1
Status
Active not recruiting
Enrollment
222
Lead sponsor
Revolution Medicines, Inc.
Conditions
Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma; Advanced Solid Tumor
Interventions
DRUG: RMC-6291
Design
Single group · None
Primary purpose
Treatment
Start
2022-09-19
Primary completion
2027-03-31
Completion
2027-09-30
Primary outcomes
  • Adverse events (up to 3 years)
  • Dose Limiting Toxicities (The first 21 days (i.e. Cycle 1))

NCT05462717 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials